Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019 provided the first two PrEP options for HIV prevention in individuals who are HIV-negative but at risk of sexually acquired HIV-1 infection. The FDA’s approval of ViiV’s Apretude (cabotegravir) in December 2021 will provide an additional option and enable preferential prescribing to the HIV PrEP-eligible population. In addition, many late-phase PrEP therapies, such as Gilead’s lenacapavir and Merck’s islatravir, are expected to offer less-frequent dosing, as well as improved safety, to become key differentiating attributes in HIV prevention. The HIV PrEP market will continue to grow owing to the launch of generic versions of Truvada, increasing initiatives by the government and companies to provide free PrEP drugs, and growing awareness of PrEP that will lead to an increase in the target population. In this report, we explore the clinical and commercial potential of approved and emerging HIV PrEP therapies.
United States, EU5, Japan
17 country-specific interviews with thought-leading infectious disease and internal medicine physicians
Supported by survey data collected for this and other Clarivate research
Number of PrEP-eligible populations by country
10-year, annualized, drug-level sales and patient share of key HIV PrEP therapies through 2031, segmented by brands / generics
Phase III / PR / Approved: 2 drugs; coverage of select early-phase products
Marketed drugs: 3
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.